Key result
Clinically evident cardiac allograft rejection linked to ~80% fewer PD-L1+ cells than silent rejection.
Why the study?
Guideline-directed histologic grading of endomyocardial biopsy tissue samples for heart transplant rejection surveillance has limited diagnostic accuracy.
Does quantitative in situ immune profiling of heart transplant biopsies improve diagnostic accuracy and rejection risk stratification compared to standard histologic grading?
Cohort (n=46)
Blinded outcome assessment
No
Does quantitative in situ immune profiling of heart transplant biopsies improve diagnostic accuracy and rejection risk stratification compared to standard histologic grading?
In situ immune profiling of heart transplant biopsies identifies specific immune cell populations that correlate with clinical rejection trajectories, potentially improving diagnostic accuracy over standard histologic grading.
Answers are grounded in this paper and cite their sources.
May support refined rejection phenotyping in transplants; leaves open whether profiling improves stratification over histology.
Recognizing that guideline-directed histologic grading of endomyocardial biopsy tissue samples for rejection surveillance has limited diagnostic accuracy, quantitative, in situ characterization was performed of several important immune cell types in a retrospective cohort of clinical endomyocardial tissue samples. Differences between cases were identified and were grouped by histologic grade versus clinical rejection trajectory, with significantly increased programmed death ligand 1+, forkhead box P3+, and cluster of differentiation 68+ cells suppressed in clinically evident rejections, especially cases with marked clinical-histologic discordance. Programmed death ligand 1+, forkhead box P3+, and cluster of differentiation 68+ cell proportions are also significantly higher in "never-rejection" when compared with "future-rejection." These findings suggest that in situ immune modulators regulate the severity of cardiac allograft rejection.
No takes yet. Share an insight, caveat, or question.
Peyster et al. (2020) conducted a cohort in Cardiac allograft rejection in heart transplant recipients (n=46). Quantitative multiplex immunofluorescence (QmIF) in situ immune profiling (CD3, CD8, CD68, FoxP3, PD-L1) in clinically evident rejection vs. Clinically silent cardiac allograft rejection was evaluated on Proportion of PD-L1+ immune-modulating cells in endomyocardial biopsy tissue (p=<0.001). Quantitative multiplex immunofluorescence showed lower PD-L1+ and FoxP3+ cells in clinically evident vs silent cardiac allograft rejection.
Synapse has enriched 10 related papers. Consider them for comparative context: